Table 2. Epicardial Adipose Tissue Volume Associations with HIV-disease related parameters in HIV-infected Men (n= 579).

	Effect estimate (95% CI)	p-value
Years since HAART initiation (per 1 year increase)	1.15(0.17,2.14)	0.02
Protease Inhibitor Therapy (per year)	0.38(-0.49,1.25)	0.40
Azidothymidine (AZT) Therapy (per year)	0.94(0.01,1.87)	0.048
Stavudine (d4T) therapy (per year)	-0.31(-1.81,1.18)	0.68
Abacovir (ABC) therapy (per year)	0.26(-1.09,1.61)	0.71
ART therapy Pre-HAART (yes vs. no)	-1.52(-10.21,7.17)	0.73
Undetectable Viral load (yes vs. no)*	7.32(-3.43,18.07)	0.18
Viral Load (log 10) †	-3.73(-10.82,3.37)	0.30
Peak Viral load (log 10)	2.31(-2.48,7.11)	0.34
Pre-HAART Viral load (log 10)	3.64(-0.16,7.43)	0.06
Current CD4 count (per 100 cell increase)	0.49(-1.12,2.10)	0.55
Nadir CD4 count (per 100 cell increase)	-0.66(-3.3,1.98)	0.63
Pre-HAART CD4 count (per 100 cell increase)	-0.89(-2.73,0.95)	0.35
History of AIDS (yes vs. no)	-1.44(-13.36,10.48)	0.81

^*Defined as viral load < 50 copies/ml compared to those with viral load>50 copies/ml.

^†Among men with detectable viral load. All analyses are adjusted for age, race and CAD risk factors including use of antihypertensive medications, systolic blood pressure (among those not on antihypertensive medications), use of diabetes medications, fasting glucose (among those not on diabetes medications), use of lipid medication use, triglyceride levels (among those not on lipid medications) and smoking (cumulative pack years). HAART= highly active anti-retroviral medical therapy